Stay updated on AstraZeneca PLC ADR Press Releases

Sign up to get notified when there's something new on the AstraZeneca PLC ADR Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the AstraZeneca PLC ADR Press Releases page

  1. Check
    yesterday
    Change Detected
    Summary
    New press release entries were added to the Media Centre, including DESTINY-Lung04 phase III results for Enhertu in HER2-mutant NSCLC, an update on the eVOLVE-Lung02 trial, and results for Tagrisso plus Orpathys in MET-driven EGFR-mutated lung cancer, with the date 17 August 2026 noted. The list also removed several older items, including the Zegfrovy licensing agreement for lung cancer, the CARDIO-TTRansform update for Wainua, and Enhertu EU tumor-agnostic approval.
    Difference
    5%
    Check dated 2026-08-18T16:02:37.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    A new press release entry dated 31 July 2026 about Datroway's EU approval and overall survival benefit for first-line metastatic TNBC was added to the press releases list. An older entry from 28 June 2026 about Efzimfotase alfa in pediatric hypophosphatasia was removed.
    Difference
    0.9%
    Check dated 2026-08-04T09:35:56.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    New press releases were added to the page, highlighting trial updates, regulatory recommendations, and 2026 results for multiple programs. Several older releases were removed to keep the archive current.
    Difference
    5%
    Check dated 2026-07-28T05:43:42.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    A new press release item dated 14 July 2026 announces an exclusive global license for the EGFR inhibitor Zegfrovy with Dizal Pharmaceutical. The EMERALD-3 trial result press release from 01 June 2026 has been removed.
    Difference
    0.9%
    Check dated 2026-07-20T22:25:53.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    A new press release entry dated 09 July 2026 about the CARDIO-TTRansform trial has been added, and the 29 May 2026 CARES Phase III update has been removed from the archive.
    Difference
    0.9%
    Check dated 2026-07-13T21:00:20.000Z thumbnail image
  7. Check
    51 days ago
    Change Detected
    Summary
    The page adds new June 2026 press releases (Enhertu EU approval, Efzimfotase alfa trial results, Datroway CHMP recommendation) and removes older US approvals (Imfinzi, Datroway), aligning the listing with current company news.
    Difference
    5%
    Check dated 2026-06-29T10:55:18.000Z thumbnail image

Stay in the know with updates to AstraZeneca PLC ADR Press Releases

Enter your email address, and we'll notify you when there's something new on the AstraZeneca PLC ADR Press Releases page.